HIV, hepatitis B, and hepatitis C in Zambia

Journal of Global Infectious Diseases

Volumn 3, Issue 3, 2011, Pages 269-274

  Kapembwa, Kenneth C ^a,b   Goldman, Jason D ^c,d   Lakhi, Shabir ^a,b   Banda, Yolan ^d   Bowa, Kasonde ^b   Vermund, Sten H ^d,e   Mulenga, Joseph ^f   Chama, David ^f   Chi, Benjamin H ^d,g  

^a UNIVERSITY OF ZAMBIA   (Zambia)

^b UNIVERSITY TEACHING HOSPITAL   (Zambia)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Zambia Blood Transfusion Service   (Zambia)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Africa; Hepatitis B; Hepatitis C; HIV; Prevalence; Zambia

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

ADOLESCENT; ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; SCREENING; TERTIARY HEALTH CARE; ZAMBIA;

EID: 80051873985     PISSN: 0974777X     EISSN: 09748245     Source Type: Journal    
DOI: 10.4103/0974-777X.83534     Document Type: Article

References (46)

1. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: Feasibility and early outcomes. JAMA 2006;296:782-93. (Pubitemid 44223102)
2. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM, Chi BH, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 2007;298:1888-99. (Pubitemid 350005233)
3. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology 2002;35:182-9. (Pubitemid 34032559)
4. Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001;15:1261-8. (Pubitemid 32592358)
5. de Maat MM, ter Heine R, van Gorp EC, Mulder JW, Mairuhu AT, Beijnen JH. Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. AIDS 2003;17:2209-14. (Pubitemid 37338894)
6. Aceti A, Pasquazzi C, Zechini B, De Bac C. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: The role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002;29:41-8. (Pubitemid 34094305)
7. Arribas JR, Ibanez C, Ruiz-Antoran B, Pena JM, Esteban-Calvo C, Frias J, et al. Acute hepatitis in HIV-infected patients during ritonavir treatment. AIDS 1998;12:1722-4. (Pubitemid 28418348)
8. Oshitani H, Kasolo FC, Mpabalwani M, Mizuta K, Luo NP, Suzuki H, et al. Prevalence of hepatitis B antigens in human immunodeficiency virus type 1 seropositive and seronegative pregnant women in Zambia. Trans R Soc Trop Med Hyg 1996;90:235-6. (Pubitemid 26188858)
9. Kasolo F, Sakala I, Baboo K. Hepatitis B virus infection in human immunodeficiency virus seropositive patients at the University Teaching Hospital, Lusaka, Zambia: Interrelationship. [Abstract no. 963]. 2 nd IAS. Paris, France: Conference on HIV Pathogenesis and Treatment; 2003.
10. Mwaba P, Zulu I, Kafula T, Chisembele M, Mtonga V, Kankasa C, et al. The GRZ ARV Pilot Program: The UTH Experience. Zambia Med J 2004;6:118-20.
11. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings. Geneva: towards universal access; 2006.
12. Morris MB, Chapula BT, Chi BH, Mwango A, Chi HF, Mwanza J, et al. Use of task-shifting to rapidly scale-up HIV treatment services: Experiences from Lusaka, Zambia. BMC Health Serv Res 2009;9:5
13. AIDS Clinical Trials Group. Table of grading severity of adult adverse experiences. Rockville, MD: Division of AIDS, National Institutes of Allergy and Infectious Diseases; 2004.
14. Hepatitis B virus infection in human innumodeficiency virus seropositive patients at the University Teaching Hospital, Lusaka, Zambia: Interrelationship [abstract no. 963]. Paris, France: 2 nd IAS Conference on HIV Pathogenesis and Treatment; 2003.
15. Firnhaber C, Reyneke A, Schulze D, Malope B, Maskew M, MacPhail P, et al. The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. S Afr Med J 2008;98:541-4.
16. Otegbayo JA, Taiwo BO, Akingbola TS, Odaibo GN, Adedapo KS, Penugonda S, et al. Prevalence of hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected patients. Ann Hepatol 2008;7:152-6. (Pubitemid 351845527)
17. Diop-Ndiaye H, Toure-Kane C, Etard JF, Lo G, Diaw P, Ngom-Gueye NF, et al. Hepatitis B, C seroprevalence and delta viruses in HIV-1 Senegalese patients at HAART initiation (retrospective study). J Med Virol 2008;80:1332-6. (Pubitemid 351897402)
18. Nagu TJ, Bakari M, Matee M. Hepatitis A, B and C viral co-infections among HIV-infected adults presenting for care and treatment at Muhimbili National Hospital in Dar es Salaam, Tanzania. BMC Public Health 2008;8:416.
19. Hadler SC, Judson FN, O'Malley PM, Altman NL, Penley K, Buchbinder S, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991;163:454-9.
20. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-10. (Pubitemid 29168769)
21. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-6. (Pubitemid 35472132)
22. Puoti M, Bruno R, Soriano V, Donato F, Gaeta GB, Quinzan GP, et al. Hepatocellular carcinoma in HIV-infected patients: Epidemiological features, clinical presentation and outcome. AIDS 2004;18:2285-93. (Pubitemid 39620221)
23. Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, Moschidis Z, Sypsa V, Zavitsanos X, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: A cohort study and meta-analysis. Clin Infect Dis 2009;48:1763-71.
24. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009;58:1-207.
25. World Health Organization. Rapid advice: Antiretroviral therapy for HIV infection for adults and adolescents, November 2009. Geneva: WHO Press, 2009.
26. Zambian Ministry of Health. Adult and adolescent antiretroviral therapy protocols. Lusaka, Zambia: Printech Press, 2010.
27. Matthews GV, Seaberg E, Dore GJ, Bowden S, Lewin SR, Sasadeusz J, et al. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS 2009;23:1707-15.
28. Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat P, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 2008;48:1062-9.
29. Chi BH, Mwango A, Giganti M, Mulenga LB, Tambatamba-Chapula B, Reid SE, et al. Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. J Acquir Immune Defic Syndr 2010;54:63-70.
30. World Health Organization. WHO vaccine preventable disease monitoring system: 2010 global summary. Available from: http://apps.who.int/immunization- monitoring/en/globalsummary/countryprofileselect.cfm. [Last Accessed on 2011 Jan 20].
31. Burnett RJ, Francois G, Kew MC, Leroux-Roels G, Meheus A, Hoosen AA, et al. Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: A call for further investigation. Liver Int 2005;25:201-13.
32. Lukhwareni A, Burnett RJ, Selabe SG, Mzileni MO, Mphahlele MJ. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital. J Med Virol 2009;81:406-12.
33. Pang T, Peeling RW. Diagnostic tests for infectious diseases in the developing world: Two sides of the coin. Trans R Soc Trop Med Hyg 2007;101:856-7. (Pubitemid 47091458)
34. Yager P, Domingo GJ, Gerdes J. Point-of-care diagnostics for global health. Annu Rev Biomed Eng 2008;10:107-44.
35. Wester CW, Bussmann H, Moyo S, Avalos A, Gaolathe T, Ndwapi N, et al. Serological evidence of HIV-associated infection among HIV-1-infected adults in Botswana. Clin Infect Dis 2006;43:1612-5. (Pubitemid 44901905)
36. Rouet F, Chaix ML, Inwoley A, Msellati P, Viho I, Combe P, et al. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Cote d'Ivoire: The ANRS 1236 study. J Med Virol 2004;74:34-40. (Pubitemid 38988857)
37. Shimelis T, Torben W, Medhin G, Tebeje M, Andualm A, Demessie F, et al. Hepatitis B virus infection among people attending the voluntary counselling and testing centre and anti-retroviral therapy clinic of St Paul's General Specialised Hospital, Addis Ababa, Ethiopia. Sex Transm Infect 2008;84:37-41. (Pubitemid 351195851)
38. Mboto CI, Fielder M, Davies-Russell A, Jewell AP. Hepatitis C virus prevalence and serotypes associated with HIV in The Gambia. Br J Biomed Sci 2010;67:140-4.
39. Harania RS, Karuru J, Nelson M, Stebbing J. HIV, hepatitis B and hepatitis C coinfection in Kenya. AIDS 2008;22:1221-2.
40. Moore E, Beadsworth MB, Chaponda M, Mhango B, Faragher B, Njala J, et al. Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection. J Infect 2010;61:155-63.
41. Nyirenda M, Beadsworth MB, Stephany P, Hart CA, Hart IJ, Munthali C, et al. Prevalence of infection with hepatitis B and C virus and coinfection with HIV in medical inpatients in Malawi. J Infect 2008;57:72-7.
42. Ahmed SD, Cuevas LE, Brabin BJ, Kazembe P, Broadhead R, Verhoeff FH, et al. Seroprevalence of hepatitis B and C and HIV in Malawian pregnant women. J Infect 1998;37:248-51. (Pubitemid 29017271)
43. Pirillo MF, Bassani L, Germinario EA, Mancini MG, Vyankandondera J, Okong P, et al. Seroprevalence of hepatitis B and C viruses among HIV-infected pregnant women in Uganda and Rwanda. J Med Virol 2007;79:1797-801. (Pubitemid 350006301)
44. Di Bisceglie AM, Maskew M, Schulze D, Reyneke A, McNamara L, Firnhaber C. HIV-HBV coinfection among South African patients receiving antiretroviral therapy. Antivir Ther 2010;15(3 Pt B):499-503.
45. Hoffmann CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, Chaisson RE, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008;47:1479-85.
46. Kallestrup P, Zinyama R, Gomo E, Dickmeiss E, Platz P, Gerstoft J, et al. Low prevalence of hepatitis C virus antibodies in HIV-endemic area of Zimbabwe support sexual transmission as the major route of HIV transmission in Africa. AIDS 2003; 17:1400-2. (Pubitemid 36819859)